Literature DB >> 11368975

Effects on sleep and wakefulness of the injection of hypocretin-1 (orexin-A) into the laterodorsal tegmental nucleus of the cat.

M C Xi1, F R Morales, M H Chase.   

Abstract

Anatomical data demonstrate a dense projection, in the cat, from hypocretin (orexin) neurons in the hypothalamus to the laterodorsal tegmental nucleus (LDT), which is a critical pontine site that is involved in the regulation of the behavioral states of sleep and wakefulness. The present study was therefore undertaken to explore the hypocretinergic control of neurons in the LDT vis-à-vis these behavioral states. Accordingly, hypocretin-1 was microinjected into the LDT of chronic, unanesthetized cats and its effects on the percentage, latency, frequency and duration of wakefulness, quiet (non-REM) sleep and active (REM) sleep were determined. There was a significant increase in the time spent in wakefulness following the microinjection of hypocretin-1 into the LDT and a significant decrease in the time spent in active sleep. The increase in the percentage of wakefulness was due to an increase in the duration of episodes of wakefulness; the reduction in active sleep was due to a decrease in the frequency of active sleep episodes, but not in their duration. These data indicate that hypocretinergic processes in the LDT play an important role in both of the promotion of wakefulness and the suppression of active sleep.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11368975     DOI: 10.1016/s0006-8993(01)02317-4

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  51 in total

1.  Neuropharmacology of Sleep and Wakefulness.

Authors:  Christopher J Watson; Helen A Baghdoyan; Ralph Lydic
Journal:  Sleep Med Clin       Date:  2010-12

2.  Exclusive postsynaptic action of hypocretin-orexin on sublayer 6b cortical neurons.

Authors:  Laurence Bayer; Mauro Serafin; Emmanuel Eggermann; Benoît Saint-Mleux; Danièle Machard; Barbara E Jones; Michel Mühlethaler
Journal:  J Neurosci       Date:  2004-07-28       Impact factor: 6.167

Review 3.  Energy expenditure: role of orexin.

Authors:  Jennifer A Teske; Vijayakumar Mavanji
Journal:  Vitam Horm       Date:  2012       Impact factor: 3.421

Review 4.  The hypocretins/orexins: integrators of multiple physiological functions.

Authors:  Jingcheng Li; Zhian Hu; Luis de Lecea
Journal:  Br J Pharmacol       Date:  2014-01       Impact factor: 8.739

Review 5.  The effect of intermittent fasting during Ramadan on sleep, sleepiness, cognitive function, and circadian rhythm.

Authors:  Shaden O Qasrawi; Seithikurippu R Pandi-Perumal; Ahmed S BaHammam
Journal:  Sleep Breath       Date:  2017-02-11       Impact factor: 2.816

6.  Dual orexin actions on dorsal raphe and laterodorsal tegmentum neurons: noisy cation current activation and selective enhancement of Ca2+ transients mediated by L-type calcium channels.

Authors:  K A Kohlmeier; S Watanabe; C J Tyler; S Burlet; C S Leonard
Journal:  J Neurophysiol       Date:  2008-07-30       Impact factor: 2.714

7.  The effect of clomipramine on wake/sleep and orexinergic expression in rats.

Authors:  P Feng; Y Hu; D Li; D Vurbic; H Fan; S Wang; K P Strohl
Journal:  J Psychopharmacol       Date:  2008-06-18       Impact factor: 4.153

8.  Selective action of orexin (hypocretin) on nonspecific thalamocortical projection neurons.

Authors:  Laurence Bayer; Emmanuel Eggermann; Benoît Saint-Mleux; Danièle Machard; Barbara E Jones; Michel Mühlethaler; Mauro Serafin
Journal:  J Neurosci       Date:  2002-09-15       Impact factor: 6.167

9.  Optogenetic deconstruction of sleep-wake circuitry in the brain.

Authors:  Antoine Adamantidis; Matthew C Carter; Luis de Lecea
Journal:  Front Mol Neurosci       Date:  2010-01-20       Impact factor: 5.639

10.  Hypocretin/Orexin neuropeptides: participation in the control of sleep-wakefulness cycle and energy homeostasis.

Authors:  A Nuñez; M L Rodrigo-Angulo; I De Andrés; M Garzón
Journal:  Curr Neuropharmacol       Date:  2009-03       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.